Clinical trials: Immune System Disease
Diffuse Large B-cell Lymphoma
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
In the current protocol version, there are two parts. Part I is a pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in…
- Trial name
- DALY 2-EU (NCT04844866)
- Testing
- MB-CART2019.1, Standard of Care
- Where
- 51 sites in Austria, Belgium and 12 more
- Volunteers
- 213 people
- Sponsor
- Miltenyi Biomedicine GmbH
Multiple Myeloma
Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
This is a multicenter, open label clinical trial evaluating the safety of the combination of belantamab mafodotin + the combination treatment VRd (bortezomib, lenalidomide, dexamethasone) in newly diagnosed (ND) transplant…
- Trial name
- NCT04802356
- Testing
- Belantamab mafodotin, Bortezomib, Lenalidomide
- Where
- 12 sites in Spain
- Volunteers
- 50 people
- Sponsor
- PETHEMA Foundation
Rheumatoid Arthritis
Prospective Cohort Study on Refractory Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic erosive arthritis. Without timely and appropriate treatment, it can lead to joint destruction and disability.
- Trial name
- NCT07126431
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University Third Hospital
Asthma Childhood, Exercise
Active Airways for Children and Young People With Asthma
What is this study about? The investigators want to see if exercise and education sessions can help children and young people (aged 10-17) with asthma, manage the participants asthma better.
- Conditions
- Asthma Childhood, Exercise, Children
- Trial name
- NCT07643753
- Testing
- EXERCISE TRAINING WITH OR WITHOUT MEDICATION, education
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Leicester
Arthritis, Rheumatoid
Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis
The purpose of this study is to determine whether milnacipran reduces widespread, non-joint pain in patients with rheumatoid arthritis (RA).
- Trial name
- NCT01207453
- Testing
- Milnacipran
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Brigham and Women's Hospital
Lymphoma, B Cell Lymphoma
CD30 CAR-T in the Treatment of CD30 Positive Lymphoma
The is a prospective, open-label, dose-climbing multicenter clinical study assessing the efficacy and safety of CD30 CAR-T in the treatment of r/r CD30+ lymphoma. Plan to recruit 15 subjects with r/r CD30+ lymphoma。
- Conditions
- Lymphoma, B Cell Lymphoma, CD30+ Peripheral T-cell Lymphoma
- Trial name
- CAR-T，MTD (NCT07048353)
- Testing
- chimeric antigen receptor gene modified T cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shandong Qilu Cell Therapy Engineering Technology Co., Ltd
Lymphoma
Molecular Epidemiology of Lymphoma Patients
Primary Objectives: 1. To enroll and obtain, through questionnaires, risk factor information on all study participants to develop detailed demographic, epidemiologic and behavioral profiles. 2.
- Trial name
- NCT00488553
- Testing
- Questionnaire
- Volunteers
- healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Asthma
Real Life Effectiveness in Patients With Not Optimally Controlled Asthma
A non-interventional study to explore actual asthma control status in real-life environment and to observe the efficacy after stepped-up to Symbicort SMART or various identical regimens.
- Trial name
- NCT00784953
- Where
- 6 sites in Taiwan
- Volunteers
- 842 people
- Sponsor
- AstraZeneca
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
All males and females between 18-70 years of age regardless of their race and ethnicity with a confirmed diagnosis of Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), and Relapse…
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT05663853
- Where
- 4 sites in United States
- Volunteers
- 137 people
- Sponsor
- LAPIX Therapeutics Inc.
Allergy Milk
Step Down Approach in Children With Cow Milk Allergy
Cow's milk allergy (CMA) affects up to 3% of European children. In the absence of an alternative to cow's milk, the management of CMA is based on the use of safe, affordable and nutritionally adequate formulas.
- Trial name
- SDACMA (NCT03449537)
- Testing
- extensively hydrolyzed casein formula + LGG, Hypoallergenic formula based on amino-acid based formula
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Federico II University
Lymphoma, B-Cell Refractory
Exploration of Circular RNA in B-cell Hematologic Malignancies
This is an investigator-initiated, open-label, single-arm, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics (PD), and preliminary efficacy of an in vivo circular RNA chimeric…
- Trial name
- NCT07774572
- Testing
- Investigational product (IP)
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Rheumatoid Arthritis
RHEUPP - A Rheumatological Follow-up Management App
The purpose of this Non-inferiority Randomized Clinical Trial is to evaluate the effectiveness of RHEUPP App during telehealth follow-up in a population of Rheumatoid Arthritis patients from a Tertiary Rheumatology Service in…
- Trial name
- RHEUPP (NCT06217172)
- Testing
- RHEUPP App, Usual Follow-up
- Volunteers
- 88 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Asthma
Pediatric Ease of Use ELLIPTA Items
A range of devices has been developed to administer inhaled therapy for asthma, including dry powder inhaler (DPI) devices. ELLIPTA is a DPI that is preloaded with a drug therapy to treat asthmatic subjects.
- Trial name
- NCT03315572
- Testing
- Interviewer administered version of ease of use items, Self-administered version of ease of use items, Caregiver version of ease of use items
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Phase 2, Radiotherapy-Induced Immune Priming
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.
- Conditions
- Phase 2, Radiotherapy-Induced Immune Priming, Elranatamab, Relapsed Refractory Multiple Myeloma (RRMM)
- Trial name
- NCT07382739
- Testing
- Elranatamab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lymphoma
A Study of Actonel for the Prevention of Bone Loss
The goal of this clinical research study is to learn if Actonel (risedronate) can help to prevent the development of osteoporosis (brittle and weak bones) caused by the steroid medication used to treat leukemia.
- Trial name
- NCT00452439
- Testing
- Actonel (Risedronate), Calcium, Vitamin D
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- M.D. Anderson Cancer Center
Previously Untreated and Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma
Study of Ipilimumab in the Immune System
Participants will be taking 3 mg/kg ipilimumab intravenously over a 90-minute period every 3 weeks for a total of four doses. Tumor-infiltrating lymphocytes (TILs)will be analyzed for functional characteristics.
- Trial name
- NCT01715077
- Testing
- Ipilimumab at 3 mg/kg dose
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- University Health Network, Toronto
Autoimmune Diseases, Systemic Lupus Erthematosus (SLE)
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
This is an exploratory, open-label, single-arm Phase 1 clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of QT-219C.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
- Trial name
- NCT07507201
- Testing
- UCAR T-cell
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Infant Botulism, Botulism
Study of Human Botulism Immunoglobulin in Infants With Botulism
OBJECTIVES: I. Determine the safety of human botulism immune globulin (BIG) in patients with infant botulism by monitoring side effects (e.g., rash, fever, hypotension, and anaphylaxis). II.
- Trial name
- NCT00004401
- Testing
- botulism immune globulin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- California Department of Health Services
Relapsed Cancer, Refractory Multiple Myeloma
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
The main goal of this phase II study is to evaluate the overall response rate of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
- Conditions
- Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma
- Trial name
- ISABELA (NCT05922501)
- Testing
- Isatuximab, Belantamab mafodotin, Pomalidomide
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Chronic Lymphocytic Leukemia
Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia
The rationale of the study is to explore the safety and efficacy of ofatumumab in combination with dexamethasone (O-dex regimen) in patients with refractory/relapsed CLL.
- Trial name
- NCT01310101
- Testing
- ofatumumab plus dexamethasone
- Where
- 4 sites in Czechia
- Volunteers
- 33 people
- Sponsor
- Brno University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.